Prospective post marketing surveillance to evaluate the safety and efficacy of etanercept under usual care settings in patients with psoriatic arthritis (PsA) treated by rheumatologists.
Phase of Trial: Phase IV
Latest Information Update: 23 Apr 2014
At a glance
- Drugs Etanercept (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Sponsors Pfizer; Wyeth
- 10 Jun 2017 Biomarkers information updated
- 14 May 2013 Planned End Date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 10 Apr 2013 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.